Lexicon Pharmaceuticals to Host Conference Call on | U.S. Markets

Lexicon Prescription drugs will talk about Part 2b research outcomes for pilavapadin in diabetic neuropathic ache on March 3, 2025.

Quiver AI Abstract

Lexicon Prescription drugs, Inc. introduced a convention call and webcast scheduled for March 3, 2025, at 8:00 a.m. ET to debate topline outcomes from the Part 2b PROGRESS research of pilavapadin (LX9211), an investigational oral AAK1 inhibitor designed for diabetic peripheral neuropathic ache (DPNP). The research concerned 496 contributors with average to extreme DPNP and assessed numerous dosages of pilavapadin in opposition to a placebo over eight weeks. The first endpoint was the change in ache scores, whereas secondary measures included evaluations of burning ache and ache interference with sleep. Diabetic peripheral neuropathic ache impacts round 9 million sufferers within the U.S., inflicting important discomfort. Lexicon goals to develop revolutionary therapies via its genomics goal discovery platform and has a portfolio that features promising candidates for numerous medical circumstances. Additional particulars might be accessed on the company’s web site.

Potential Positives

• The upcoming convention call on March 3, 2025, signifies the company’s dedication to transparency and communication with stakeholders concerning important research outcomes.
• The Part 2b PROGRESS research entails a substantial pattern measurement of 496 sufferers, suggesting strong knowledge assortment and potential for significant leads to the therapy of diabetic peripheral neuropathic ache (DPNP).
• Pilavapadin (LX9211) presents a novel non-opioid therapy option for DPNP, addressing a important unmet medical need given the continual nature of this situation affecting roughly 9 million sufferers within the U.S.
• The research’s design permits sufferers to keep up their present DPNP therapies, highlighting the potential for pilavapadin to enrich present therapies, which can improve its acceptance in scientific follow.

Potential Negatives

• Announcement of a future convention call might recommend that the company is just not ready to share substantive findings from the PROGRESS research at this time, probably resulting in investor issues in regards to the trial outcomes.
• The reliance on a Part 2b research outcomes implies the company has not but reached late-stage scientific trials, which can raise doubts in regards to the readiness and viability of pilavapadin as a marketable therapy for DPNP.
• The point out of competing therapies (e.g., gabapentin, pregabalin, duloxetine) within the context of the PROGRESS research might point out that pilavapadin faces important competitors in a crowded market for DPNP therapies.

FAQ

What’s the PROGRESS research about?

The PROGRESS research evaluates pilavapadin (LX9211) for treating diabetic peripheral neuropathic ache in adults.

When will Lexicon Prescription drugs maintain the convention call?

The convention call is scheduled for March 3, 2025, at 8:00 a.m. ET.

How can I entry the convention call?

Members can entry the call through the Occasions web page on Lexicon’s web site or by registering for dial-in numbers.

What are the important thing findings anticipated from the Part 2b research?

Topline outcomes concerning the effectiveness of pilavapadin in treating diabetic peripheral neuropathic ache shall be shared.

What’s diabetic peripheral neuropathic ache?

DPNP is a continual complication of diabetes that causes burning ache and numbness, affecting thousands and thousands of sufferers within the U.S.

Disclaimer: That is an AI-generated abstract of a press release distributed by GlobeNewswire. The model used to summarize this release might make errors. See the total release right here.

$LXRX Hedge Fund Exercise

We’ve seen 63 institutional traders add shares of $LXRX stock to their portfolio, and 70 lower their positions of their most up-to-date quarter.

Listed here are some of the biggest current strikes:

• ORBIMED ADVISORS LLC eliminated 11,024,000 shares (-100.0%) from their portfolio in This autumn 2024, for an estimated $8,141,224
• POINT72 ASSET MANAGEMENT, L.P. added 7,758,371 shares (+630.7%) to their portfolio in This autumn 2024, for an estimated $5,729,556
• SCHONFELD STRATEGIC ADVISORS LLC added 5,676,021 shares (+301.5%) to their portfolio in This autumn 2024, for an estimated $4,191,741
• NANTAHALA CAPITAL MANAGEMENT, LLC added 4,300,000 shares (+186.6%) to their portfolio in This autumn 2024, for an estimated $3,175,550
• AMERIPRISE FINANCIAL INC eliminated 2,327,110 shares (-100.0%) from their portfolio in This autumn 2024, for an estimated $1,718,570
• FMR LLC added 2,103,413 shares (+4.2%) to their portfolio in This autumn 2024, for an estimated $1,553,370
• OPALEYE MANAGEMENT INC. eliminated 1,875,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $2,943,750

To trace hedge funds’ stock portfolios, take a look at Quiver Quantitative’s institutional holdings dashboard.

Full Launch

THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) — Lexicon Prescription drugs, Inc. (Nasdaq: LXRX) at present introduced the Firm will maintain a convention call and webcast on Monday, March 3, 2025 at 8:00 a.m. ET to share topline outcomes from the Part 2b PROGRESS (A

P

hase 2b, Dose-ranging,

R

andomized, Double-blind, Placeb

O

-controlled, Parallel-

GR

oup, Multic

E

nter

S

tudy with an Open-label Extension in Affected person

S

with Diabetic Peripheral Neuropathic Ache) research evaluating pilavapadin (LX9211), an oral, non-opioid investigational adaptor-associated kinase 1 (AAK1) inhibitor in grownup sufferers with average to extreme diabetic peripheral neuropathic ache (DPNP).

Convention Name and Webcast Info

Lexicon management will maintain a reside convention call and webcast on Monday, March 3, 2025, at 8:00 a.m. ET / 7:00 a.m. CT to review the small print of this announcement. Members can entry the convention call reside through webcast on the Occasions web page of the Firm’s web site at

https://traders.lexpharma.com/

. Members who want to ask a query might register

right here

to obtain dial-in numbers and a distinctive pin to affix the call. An archived model of the webcast shall be out there on the Lexicon web site.

In regards to the PROGRESS Research

The PROGRESS research commenced in December 2023 and enrolled 496 grownup sufferers with a prognosis of diabetes (kind 1 or kind 2) and average to extreme DPNP. The research was placebo-controlled with a major endpoint of change from baseline to Week 8 in ADPS as in comparison with placebo and evaluated three therapy teams receiving as soon as each day pilavapadin doses of 10 mg, 20 mg or 20 mg for seven days adopted by 10 mg thereafter. Secondary endpoints included change from baseline to Week 8 in burning ache and ache interference on sleep. Research design permitted sufferers to stay on one stable-dose DPNP remedy (e.g. gabapentin, pregabalin or duloxetine) with out withdrawing from therapies that, though insufficient, could also be offering some benefit – aligning with how new DPNP medicine are possible for use in follow.

About Diabetic Peripheral Neuropathic Ache (DPNP)

DPNP is a debilitating continual complication of diabetes which may end up in burning ache, numbness, and different signs within the palms, ft, legs and arms. There are roughly 9 million sufferers within the U.S. who’re struggling with DPNP.

About Pilavapadin

Found utilizing Lexicon’s distinctive method to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel goal for neuropathic ache which inhibits reuptake and recycling of neurotransmitters concerned in ache signaling with out affecting opiate pathways. Lexicon recognized AAK1 in its goal discovery efforts as a promising method for the therapy of neuropathic ache. Preclinical research of pilavapadin demonstrated central nervous system penetration and discount in ache habits in fashions of neuropathic ache with out affecting opiate pathways.

About Lexicon Prescription drugs

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that remodel sufferers’ lives. By the Genome5000™ program, Lexicon’s distinctive genomics goal discovery platform, Lexicon scientists studied the function and performance of practically 5,000 genes and recognized more than 100 protein targets with important therapeutic potential in a vary of illnesses. By the exact concentrating on of these proteins, Lexicon is pioneering the invention and development of revolutionary medicines to securely and successfully deal with illness. Lexicon has superior a number of medicines to market and has a pipeline of promising drug candidates in discovery and scientific and preclinical development in coronary heart failure, neuropathic ache, weight problems, cardiology, diabetes and different indications. For extra data, please go to

www.lexpharma.com

.

For Investor and Media Inquiries

:

Lisa DeFrancesco

Lexicon Prescription drugs, Inc.

[email protected]

This text was initially printed on Quiver Information, learn the total story.

The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.